Literature DB >> 28507170

Hypertension-Causing Mutation in Peroxisome Proliferator-Activated Receptor γ Impairs Nuclear Export of Nuclear Factor-κB p65 in Vascular Smooth Muscle.

Masashi Mukohda1, Ko-Ting Lu1, Deng-Fu Guo1, Jing Wu1, Henry L Keen1, Xuebo Liu1, Pimonrat Ketsawatsomkron1, Madeliene Stump1, Kamal Rahmouni1, Frederick W Quelle1, Curt D Sigmund2.   

Abstract

Selective expression of dominant negative (DN) peroxisome proliferator-activated receptor γ (PPARγ) in vascular smooth muscle cells (SMC) results in hypertension, atherosclerosis, and increased nuclear factor-κB (NF-κB) target gene expression. Mesenteric SMC were cultured from mice designed to conditionally express wild-type (WT) or DN-PPARγ in response to Cre recombinase to determine how SMC PPARγ regulates expression of NF-κB target inflammatory genes. SMC-specific overexpression of WT-PPARγ or agonist-induced activation of endogenous PPARγ blunted tumor necrosis factor α (TNF-α)-induced NF-κB target gene expression and activity of an NF-κB-responsive promoter. TNF-α-induced gene expression responses were enhanced by DN-PPARγ in SMC. Although expression of NF-κB p65 was unchanged, nuclear export of p65 was accelerated by WT-PPARγ and prevented by DN-PPARγ in SMC. Leptomycin B, a nuclear export inhibitor, blocked p65 nuclear export and inhibited the anti-inflammatory action of PPARγ. Consistent with a role in facilitating p65 nuclear export, WT-PPARγ coimmunoprecipitated with p65, and WT-PPARγ was also exported from the nucleus after TNF-α treatment. Conversely, DN-PPARγ does not bind to p65 and was retained in the nucleus after TNF-α treatment. Transgenic mice expressing WT-PPARγ or DN-PPARγ specifically in SMC (S-WT or S-DN) were bred with mice expressing luciferase controlled by an NF-κB-responsive promoter to assess effects on NF-κB activity in whole tissue. TNF-α-induced NF-κB activity was decreased in aorta and carotid artery from S-WT but was increased in vessels from S-DN mice. We conclude that SMC PPARγ blunts expression of proinflammatory genes by inhibition of NF-κB activity through a mechanism promoting nuclear export of p65, which is abolished by DN mutation in PPARγ.
© 2017 American Heart Association, Inc.

Entities:  

Keywords:  aorta; atherosclerosis; hypertension; inflammation; mutation

Mesh:

Substances:

Year:  2017        PMID: 28507170      PMCID: PMC5472224          DOI: 10.1161/HYPERTENSIONAHA.117.09276

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  36 in total

Review 1.  Evolving functions of endothelial cells in inflammation.

Authors:  Jordan S Pober; William C Sessa
Journal:  Nat Rev Immunol       Date:  2007-10       Impact factor: 53.106

2.  Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension.

Authors:  I Barroso; M Gurnell; V E Crowley; M Agostini; J W Schwabe; M A Soos; G L Maslen; T D Williams; H Lewis; A J Schafer; V K Chatterjee; S O'Rahilly
Journal:  Nature       Date:  1999 Dec 23-30       Impact factor: 49.962

3.  Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice.

Authors:  A C Li; K K Brown; M J Silvestre; T M Willson; W Palinski; C K Glass
Journal:  J Clin Invest       Date:  2000-08       Impact factor: 14.808

4.  Endothelium-specific interference with peroxisome proliferator activated receptor gamma causes cerebral vascular dysfunction in response to a high-fat diet.

Authors:  Andreas M Beyer; Willem J de Lange; Carmen M Halabi; Mary L Modrick; Henry L Keen; Frank M Faraci; Curt D Sigmund
Journal:  Circ Res       Date:  2008-07-31       Impact factor: 17.367

5.  Dominant negative PPARγ promotes atherosclerosis, vascular dysfunction, and hypertension through distinct effects in endothelium and vascular muscle.

Authors:  Christopher J Pelham; Henry L Keen; Steven R Lentz; Curt D Sigmund
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2013-02-27       Impact factor: 3.619

6.  Rosiglitazone (PPARgamma-agonist) attenuates atherogenesis with no effect on hyperglycaemia in a combined diabetes-atherosclerosis mouse model.

Authors:  Z Levi; A Shaish; N Yacov; H Levkovitz; S Trestman; Y Gerber; H Cohen; A Dvir; R Rhachmani; M Ravid; D Harats
Journal:  Diabetes Obes Metab       Date:  2003-01       Impact factor: 6.577

7.  Interference with PPARγ in endothelium accelerates angiotensin II-induced endothelial dysfunction.

Authors:  Chunyan Hu; Ko-Ting Lu; Masashi Mukohda; Deborah R Davis; Frank M Faraci; Curt D Sigmund
Journal:  Physiol Genomics       Date:  2015-11-03       Impact factor: 3.107

8.  Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shuttling of PPAR-gamma and RelA.

Authors:  Denise Kelly; Jamie I Campbell; Timothy P King; George Grant; Emmelie A Jansson; Alistair G P Coutts; Sven Pettersson; Shaun Conway
Journal:  Nat Immunol       Date:  2003-12-21       Impact factor: 25.606

Review 9.  PPARγ signaling and metabolism: the good, the bad and the future.

Authors:  Maryam Ahmadian; Jae Myoung Suh; Nasun Hah; Christopher Liddle; Annette R Atkins; Michael Downes; Ronald M Evans
Journal:  Nat Med       Date:  2013-05-07       Impact factor: 53.440

10.  Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation.

Authors:  Jang Hyun Choi; Alexander S Banks; Theodore M Kamenecka; Scott A Busby; Michael J Chalmers; Naresh Kumar; Dana S Kuruvilla; Youseung Shin; Yuanjun He; John B Bruning; David P Marciano; Michael D Cameron; Dina Laznik; Michael J Jurczak; Stephan C Schürer; Dušica Vidović; Gerald I Shulman; Bruce M Spiegelman; Patrick R Griffin
Journal:  Nature       Date:  2011-09-04       Impact factor: 49.962

View more
  12 in total

1.  RhoBTB1 protects against hypertension and arterial stiffness by restraining phosphodiesterase 5 activity.

Authors:  Masashi Mukohda; Shi Fang; Jing Wu; Larry N Agbor; Anand R Nair; Stella-Rita C Ibeawuchi; Chunyan Hu; Xuebo Liu; Ko-Ting Lu; Deng-Fu Guo; Deborah R Davis; Henry L Keen; Frederick W Quelle; Curt D Sigmund
Journal:  J Clin Invest       Date:  2019-03-21       Impact factor: 14.808

2.  LRP1 Deficiency in Vascular SMC Leads to Pulmonary Arterial Hypertension That Is Reversed by PPARγ Activation.

Authors:  Laurent Calvier; Philippe Boucher; Joachim Herz; Georg Hansmann
Journal:  Circ Res       Date:  2019-04-26       Impact factor: 17.367

Review 3.  Angiotensin II Signal Transduction: An Update on Mechanisms of Physiology and Pathophysiology.

Authors:  Steven J Forrester; George W Booz; Curt D Sigmund; Thomas M Coffman; Tatsuo Kawai; Victor Rizzo; Rosario Scalia; Satoru Eguchi
Journal:  Physiol Rev       Date:  2018-07-01       Impact factor: 37.312

4.  PPARγ increases HUWE1 to attenuate NF-κB/p65 and sickle cell disease with pulmonary hypertension.

Authors:  Andrew J Jang; Sarah S Chang; Changwon Park; Choon-Myung Lee; Raymond L Benza; Michael J Passineau; Jing Ma; David R Archer; Roy L Sutliff; C Michael Hart; Bum-Yong Kang
Journal:  Blood Adv       Date:  2021-01-26

Review 5.  Anti-inflammatory mechanisms of the vascular smooth muscle PPARγ.

Authors:  Masashi Mukohda; Hiroshi Ozaki
Journal:  J Smooth Muscle Res       Date:  2021

6.  EP3 (E-Prostanoid 3) Receptor Mediates Impaired Vasodilation in a Mouse Model of Salt-Sensitive Hypertension.

Authors:  Jing Wu; Shi Fang; Ko-Ting Lu; Kelsey Wackman; Michal L Schwartzman; Sergey I Dikalov; Justin L Grobe; Curt D Sigmund
Journal:  Hypertension       Date:  2021-03-01       Impact factor: 9.897

Review 7.  PPARγ and RhoBTB1 in hypertension.

Authors:  Shi Fang; Curt D Sigmund
Journal:  Curr Opin Nephrol Hypertens       Date:  2020-03       Impact factor: 3.416

Review 8.  Role of the Peroxisome Proliferator Activated Receptors in Hypertension.

Authors:  Shi Fang; M Christine Livergood; Pablo Nakagawa; Jing Wu; Curt D Sigmund
Journal:  Circ Res       Date:  2021-04-01       Impact factor: 23.213

Review 9.  Molecular mechanisms and genetic regulation in atherosclerosis.

Authors:  Ampadu-Okyere Jackson; Mugwaneza Annick Regine; Chakrabarti Subrata; Shiyin Long
Journal:  Int J Cardiol Heart Vasc       Date:  2018-09-25

10.  Pioglitazone Modulates the Vascular Contractility in Hypertension by Interference with ET-1 Pathway.

Authors:  Roberto Palacios-Ramírez; Raquel Hernanz; Angela Martín; José V Pérez-Girón; María T Barrús; Zoe González-Carnicero; Andrea Aguado; Frederic Jaisser; Ana M Briones; Mercedes Salaices; María J Alonso
Journal:  Sci Rep       Date:  2019-11-11       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.